Patients with JIA-associated uveitis who discontinued adalimumab had higher recurrence rates than those who continued the ...

Set to enter hospice care, a patient with idiopathic multicentric Castleman's disease is now in remission after treatment with a medication identified by an AI-guided analysis.

After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD).

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

The patient has iMCD, which has a poor survival rate and few treatment options but an AI tool searched through 4,000 ...

Researchers used an AI-driven approach to identify adalimumab as a potential life-saving treatment for idiopathic ...

The guidelines are a first-of-its-kind effort to establish recommendations for the medical management of HS in seven different scenarios: Pregnancy, breastfeeding, pediatrics, malignancy, tuberculosis ...

UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...

Hidradenitis suppurativa is managed with biologics like adalimumab and secukinumab, approved for moderate-to-severe cases. Adalimumab, a TNF-α inhibitor, was FDA-approved in 2015, while ...